Abstract:Advances in stent technology and the design of endovascular devices with thinner struts, anti‐inflammatory and antithrombotic polymers, and better drug kinetics have enhanced the safety and efficacy of the second‐generation drug‐eluting stents and broadened their use in the therapy of high‐risk patients and complex anatomies. However, despite these developments, in‐stent restenosis and stent thrombosis remain the Achilles' heel of percutaneous coronary intervention, with their cumulative incidence reaching up to 10% at 5 years following percutaneous coronary intervention. The treatment of stent failure poses challenges and is associated with a worse prognosis than conventional percutaneous coronary intervention. Several studies have recently highlighted the value of intravascular imaging in identifying causes of stent failure, underscored its role in treatment planning, and registries have shown that its use may be associated with better clinical outcomes. The present review aims to summarize the evidence in the field; it discusses the value of intravascular imaging in identifying the mechanisms of in‐stent restenosis and stent thrombosis in assessing the morphological characteristics of neointima tissue that appears to determine long‐term outcomes in evaluating procedural results, and presents the findings of studies supporting its value in guiding therapy in stent failure. Nonstandard Abbreviations and Acronyms DCB drug‐coated balloon DES drug‐eluting stent ISR in‐stent restenosis IVBT intravascular brachytherapy POBA plain old balloon angioplasty ST stent thrombosis TLR target lesion revascularization WSS wall shear stress New developments in percutaneous coronary intervention (PCI) technology, including the design of efficient guidewires, adjunctive PCI devices, and advances in stent technology, have simplified the procedure, reduced the risk of complications, increased procedural success, and improved long‐term outcomes, especially in high‐risk patients and complex lesions. Nevertheless, in selected patients and in challenging anatomies, the event rate remains high. 1 In‐stent restenosis (ISR) constitutes the most common cause of stent failure in the United States and United Kingdom, 2 , 3 and its management is challenging because reintervention is needed in 10.3% to 36.8% of the patients at 3‐year follow‐up. 4 , 5 Although the incidence of stent thrombosis (ST) has been considerably reduced after the introduction of the second‐generation drug eluting stents (DES) as shown in clinical trials, in clinical practice, the ST rates are higher and are associated with devastating consequences, because in such cases the clinical presentation is often death or myocardial infarction. 6 , 7 , 8 Over the past years, several endovascular therapies have been introduced to successfully treat ISR that were evaluated in numerous randomized control studies (Figure S1, Table S1). Despite the undoubted value of these studies in clinical practice, they all had a significant limitation: they did not use intravascular imaging to identify the underlying mechanisms of stent failure and assess neointima characteristics that are likely to affect clinical outcomes. Intravascular imaging studies have underscored the importance of correcting causes of stent failure and the role of neointima composition on vessel wall response after repeat revascularization. Consequently, the routine use of intravascular imaging has IIa/C indication in the European Society of Cardiology guidelines for detecting causes of stent failure and personalizing therapy. 9 This review aimed to provide a comprehensive overview in the field, discusses the potential value of intravascular imaging in identifying causes of ISR and ST, presents clinical outcomes from small‐scale studies assessing different interventional strategies in challenging scenarios, and proposes a treatment algorithm that relies on the information derived from intravascular imaging to effectively treat ISR and ST. UNDERLYING MECHANISMS OF IN‐STENT RESTENOSIS The introduction of DES and developments in stent polymers and drug kinetics have si -Abstract Truncated-

Very Late Stent Thrombosis in Drug-Eluting Stents New Observations and Clinical Implications.

Predictors of in-stent stenosis and occlusion after endovascular treatment of intracranial vascular disease with the Willis covered stent.

Advancements in Prevention of Late Stent Thrombosis

[Antithrombotic therapy after iliac vein stenting].

Drug-Eluting Stent and Late Stent Thrombosis

Complications and Management of Intracoronary Stenting

Very Late Stent Thrombosis in Japan – A Look into the Future?

Factors associated with early, late, and very late stent thrombosis among patients with acute coronary syndrome undergoing coronary stent placement: analysis from the ATLAS ACS 2-TIMI 51 trial

Very Late Thrombosis in a Patient with a Drug-Eluting Stent for Intracranial Atherosclerotic Stenosis

Increased serum vWF and sVCAM-1 levels are associated with late or very late angiographic stent thrombosis after sirolimus-eluting stent implantation.

Incidence and Predictors of Definite Stent Thrombosis after Coronary Stent Implantation.

Translational research on novel drug-eluting stents in percutaneous coronary intervention

Recent Advances in Cardiovascular Stent for Treatment of In-Stent Restenosis: Mechanisms and Strategies

Intravascular Imaging for Guiding In‐Stent Restenosis and Stent Thrombosis Therapy

In-Stent Restenosis: Achilles’ Heel of Post-PCI Era

Advances in Intravascular Imaging Techniques to Guide Stent Thrombosis Prevention and Researching Mechanisms

Drug-Eluting Stent Restenosis: Modern Approach to a Classic Challenge

Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.

Acute Coronary Stent Thrombosis in Modern Era: Etiology, Treatment, and Prognosis

A case of very late stent thrombosis on the protruded struts at the left main coronary bifurcation

Current status and prospect of drug-eluting stents